People · Operator
Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Prosensa Holding N.V. | — | Biotechnology | Series C | $50.5M | $2.1B | 2014 |
Hans Schikan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Hans Schikan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Mott | 1 | 9 |
| Annalisa Jenkins | 1 | 8 |
| Michael Wyzga | 1 | 5 |
| Luc Dochez | 1 | 4 |
| Martijn Kleijwegt | 1 | 2 |
| Giles Campion | 1 | 2 |
| Berndt Modig | 1 | 2 |
| Peter Goodfellow | 1 | 2 |
| Daan Ellens | 1 | 1 |
| Georges Gemayel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.